Is NCT06928272 recruiting in San Diego, CA?

Yes, NCT06928272 is currently recruiting participants at its San Diego, CA location. This long covid clinical trial is actively enrolling qualified participants.

How do I join the long covid clinical trial in San Diego?

To join this clinical trial in San Diego, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this San Diego clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Long COVID Clinical Trial in San Diego, CA

About This Long COVID Study in San Diego

The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months. The main goal of the study is to determine whether the drug treatments can improve symptoms in five key areas: 1) fatigue, 2) breathing, 3) memory, thinking, and communication, 4) muscle and joint pain, and 5) circulation. A secondary goal is to assess changes in the body, such as reducing inflammation, as well as to confirm the safety and tolerability of the treatments. In the first phase, 348 participants will take either one of two existing medications (upadacitinib or pirfenidone) or a placebo (a pill with no active ingredient) for three months. Although these medications are not yet approved for Long Covid, they are authorized for use in treating other health conditions. This study is adaptive, meaning it may adjust based on early results. In the second phase, the study could continue testing the most effective drug(s) against a placebo with new participants, explore combinations of drugs to see if they improve results, or discontinue the drugs if they prove ineffective or unsafe and test alternative treatments.

Sponsor: Douglas D. Fraser

Who Can Participate

Inclusion Criteria

Eligible participants must meet all the following inclusion criteria:

Adults ≥ 18 years of age and ≤ 65 years of age

Previous Covid-19 (SARS-CoV-2 infection) within the past four years, as determined by the site investigator using the following certainty scale (based on available clinical history and/or serologic data): 3 - Confirmed Infection (PCR or n-Capsid Test): Prior positive nasopharyngeal or salivary PCR test for Covid-19 (documented proof and/or verbal confirmation by participant) or has positive nucleocapsid antibodies results. 2 - Probable Infection (Antigen Test): Participant verbally confirms a prior positive rapid antigen test without PCR confirmation. 1 - Possible Infection (Viral Syndrome and Epidemiological Link): Participant verbally confirms experiencing symptoms consistent with Covid-19 infection and has an epidemiological link (i.e., exposure to a confirmed case) without any positive testing. 3\. Persistent or new symptoms diagnosed as "Long Covid" as defined by the World Health Organization; "the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection (Covid-19), with these symptoms lasting for at least 2 months with no other explanation". This diagnosis may come from a healthcare professional experienced in Long Covid diagnosis, or the site investigator. These symptoms must be present for more days than not and must not have been present prior to the onset of SARS-CoV-2 (Covid-19) infection. 4\. At the time of screening, participants should be experiencing at least one of the following self-reported symptoms or symptom clusters. Participant has self-reported issues with:

Circulation

Memory, thinking, and/or communication

Muscles and/or joints These five symptoms or symptom clusters were selected based on unpublished data from the National Institutes for Health and Care Research (NIHR, United Kingdom) and their alignment with five validated SBQ scales. The selection was driven by their prevalence and their significant impact on quality of life as reported in symptom assessments. 5\. Participant has the ability and is willing to follow study procedures throughout the study 6\. Participant can provide informed consent

Exclusion Criteria

Participants who have any one or more of the following criteria at the time of enrollment will be excluded:

Participants who do not meet the criteria outlined above

Participants who are unable to provide their informed consent

Participants who are pregnant, lactating, or plan to become pregnant during the time of the study

Persons of childbearing potential who are unwilling or unable to abstain from sex or to use at least one acceptable method of contraception from the time of screening through at least 30 days after the end of the study intervention period. Acceptable methods include barrier contraceptives (e.g., condoms or diaphragm) with spermicide, intrauterine devices (IUDs), hormonal contraceptives, oral contraceptive pills, and surgical sterilization. Participants unwilling to be counseled about the risks related to pregnancy or breastfeeding will also be excluded.

Male participants must take precautions to avoid impregnating a female while participating in this study. If a male participant's partner can become pregnant, she must use an effective and reliable form of birth control, as listed above, during the study and for 30 days after the male participant's last dose of the investigational product. Additionally, male participants must agree to use a latex condom during sexual activity with partners who could become pregnant.

eGFR \<30 mL/min/1.73m2

Moderate to severe liver dysfunction, defined as Bilirubin \> 1.5 x ULN or AST or ALT \> 2 x ULN

Hemoglobin (Hbg) \< 8.0 g/dL

Absolute neutrophil count (ANC) below 1,000 cells/mm³, confirmed with repeat testing

Absolute lymphocyte count (ALC) below 500 cells/mm³

Alkaline phosphatase (ALP) levels equal to or greater than three times the upper limit of normal (ULN)

Creatine phosphokinase (CPK) levels equal to or greater than three times the ULN

Platelet count below 100,000 cells/mm³, confirmed with repeat testing

Platelet count above 500,000 cells/mm³, confirmed with repeat testing

Total fasting cholesterol levels of 280 mg/dL or higher, confirmed with repeat testing

Fasting low-density lipoprotein (LDL) levels of 180 mg/dL or higher, confirmed with repeat testing

A personal or family history of long QT syndrome or an electrocardiogram (ECG) during screening showing a corrected QT interval (QTc) of 500 milliseconds or greater, calculated using Fridericia's formula

Participants with HIV diagnosis

Participants with active hepatitis B or C diagnosis. Note: treated or cleared hepatitis C is not exclusionary.

Active herpes zoster infection (visible skin lesions) within 3 months prior to screening, or any history of disseminated or complicated herpes zoster or herpes simplex infection (e.g., VZV encephalitis)

Participants with active or latent tuberculosis

Immunocompromised status, as determined by the investigator, that places the participant at an unacceptable risk for study participation

Active malignancy or lymphoproliferative disorder that has not been in remission for at least five years. Localized non-melanoma skin cancers that have been definitively treated are not exclusionary.

Positive SARS-CoV-2 test in the last 30 days or symptomatic with Covid-19 like illness

Previous admission to an intensive care unit (ICU) for the treatment of acute COVID-19 infection

Any history of deep venous thrombosis, pulmonary embolism, unstable angina, atrial fibrillation, ventricular fibrillation, or myocardial infarction or stroke

History of sepsis or a significant viral, bacterial, fungal, or parasitic infection within 30 days prior to enrollment, as determined by the investigator.

Use of one or more of the study drugs within 30 days prior to enrollment for the original indication or other purposes

Known allergic reactions to the components of the study drugs

Any prior exposure to JAK inhibitors

Taking any of the listed medications on the prohibited medications list in Appendix A

Intake or planned consumption of any of the following: Taurine, Curcumin, CoQ10, Creatine, Resveratrol, Fisetin, Nicotinamide mononucleotide (NMN), Nicotinamide adenine dinucleotide (NAD+), Quercetin, Glycine, Spermidine, Arginine alpha-ketoglutarate, Ergothioneine, Alpha Lipoic Acid, Carnitine, Benfotiamine, Carnosine, Crocin, N-acetylcysteine

Covid vaccinations are prohibited within 30 days prior to enrollment

Live vaccine within the 30 days before enrollment or plan to receive live vaccines during the study period

Other vaccines, including influenza vaccine, are prohibited within 14 days of enrollment

Major surgery within 30 days prior to enrollment or plans for major surgery during the study

Any other co-existing medical condition or concomitant medication/therapy that might in the judgment of the study investigators, potentially impact the participant's safety or ability to adhere to the study protocol or interfere with the meaning of the clinical and research measurements as judged by the study investigators

Participation in any clinical study within the last 30 days prior to enrollment

Participants who participated in Phase One of this study (LC-Revitalize) are not eligible to participate in Phase Two

Currently hospitalized and/or incarcerated

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Diego?

Yes, this clinical trial (NCT06928272) has an active research site in San Diego, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Long COVID Treatment Options in San Diego, CA

If you're searching for long covid treatment options in San Diego, CA, this clinical trial (NCT06928272) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Diego research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced long covid specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all long covid clinical trials near you to find additional studies recruiting in your area.

Long COVID Clinical Trial in San Diego, CA

Expert Care in San Diego

IRB Approved

No-Cost Care

Apply for This San Diego Location

Why Participate?

Simple Process